Sumitomo Dainippon Pharma
Japan - Oita
APOMORPHINE HYDROCHLORIDE (apomorphine hydrochloride) by Sumitomo Dainippon Pharma is non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine d 4 receptor, and moderate affinity for the dopamine d 2 , d 3 , and d 5 , and adrenergic α 1 d, α 2 b, α 2 c receptors. Approved for parkinson's disease. First approved in 2022.
Drug data last refreshed 18h ago
non-ergoline dopamine agonist with high in vitro binding affinity for the dopamine D 4 receptor, and moderate affinity for the dopamine D 2 , D 3 , and D 5 , and adrenergic α 1 D, α 2 B, α 2 C receptors. The precise mechanism of action of apomorphine hydrocloride as a treatment for Parkinson's…
Worked on APOMORPHINE HYDROCHLORIDE at Sumitomo Dainippon Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.